Inhaled antibiotics for the treatment of pneumonia. [Review]

MedStar author(s):
Citation: Current Opinion in Pulmonary Medicine. 25(3):289-293, 2019 05.PMID: 30562188Institution: MedStar Washington Hospital CenterDepartment: Medicine/Pulmonary-Critical CareForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Amikacin/ad [Administration & Dosage] | *Anti-Bacterial Agents/ad [Administration & Dosage] | *Pneumonia, Bacterial/dt [Drug Therapy] | *Pneumonia, Ventilator-Associated/dt [Drug Therapy] | Administration, Inhalation | HumansYear: 2019Local holdings: Available online from MWHC library: 1999 - presentISSN:
  • 1070-5287
Name of journal: Current opinion in pulmonary medicineAbstract: PURPOSE OF REVIEW: To describe recent developments in trials exploring inhaled antibiotics for treating severe pneumonia.RECENT FINDINGS: Three recent randomized studies investigated the potential role for aerosolized antibiotics for gram-negative pneumonia in ventilated patients. One single center, nonblinded investigation suggested a benefit with inhaled amikacin for resistant gram-negative infections. However, two multicenter, blinded trials found no benefit to adjunctive nebulized amikacin for severe gram-negative pneumonia.SUMMARY: Well done clinical trials do not support the routine use of inhaled amikacin for pneumonia in ventilated patients. There may be a potential role for aerosolized antibiotics when other options are limited.All authors: Schreiber MP, Shorr AFOriginally published: Current Opinion in Pulmonary Medicine. 2018 Dec 17Fiscal year: FY2019Digital Object Identifier: Date added to catalog: 2019-01-08
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 30562188 Available 30562188

Available online from MWHC library: 1999 - present

PURPOSE OF REVIEW: To describe recent developments in trials exploring inhaled antibiotics for treating severe pneumonia.

RECENT FINDINGS: Three recent randomized studies investigated the potential role for aerosolized antibiotics for gram-negative pneumonia in ventilated patients. One single center, nonblinded investigation suggested a benefit with inhaled amikacin for resistant gram-negative infections. However, two multicenter, blinded trials found no benefit to adjunctive nebulized amikacin for severe gram-negative pneumonia.

SUMMARY: Well done clinical trials do not support the routine use of inhaled amikacin for pneumonia in ventilated patients. There may be a potential role for aerosolized antibiotics when other options are limited.

English

Powered by Koha